Abstract
Due to the high frequency of liver lesions caused by anti-tuberculosis drugs, the possibility of using compounds based on oxidized glutathione for hepatoprotection is shown.
 Purposes and tasks. The purpose of the study was to conduct a comparative assessment of the hepatoprotective properties of molixan and glutoxim in liver lesions with anti-tuberculosis drugs. To achieve this goal, it was necessary to perform the following tasks: on the model of toxic liver damage caused by anti-tuberculosis drugs (isoniazid, rifampicin, pyrazinamide) to study the effectiveness of glutoxin and molixan by biochemical and morphological parameters; on the basis of the data to determine the most effective scheme of application.
 Materials and methods: the study was conducted on 90 white male not inbred rats. Antituberculosis drugs (AD) were administered to animals daily for 14 days in the following doses: isoniazid – 50 mg/kg intraperitoneal, rifampicin – 250 mg/kg and pyrazinamide – 45 mg/kg intragastrically. Glutoxim and molixan were administered daily for 14 days at doses: 20 and 40 mg/kg – glutoxim, 30 mg/kg – molixan, intraperitoneal for 2 hours before the introduction of anti-tuberculosis drugs. The animals were divided into 5 groups of 18 rats each. Group 1 – intact animals, 2 – control AD, 3 – AD + glutoxim 20 mg/kg, 4 – AD + glutoxim 40 mg/kg, 5 – AD + molixan 30 mg/kg. In the study on day 15, biochemical parameters of blood were determined, the liver was taken for morphohistological study and the level of LPO in its homogenates was determined by the concentration of diene conjugates and malondialdehyde.
 Results and conclusions. As a result of the experimental study, it was noted that the more pronounced hepatoprotective effect was exerted by molixan.
Highlights
В связи с высокой частотой развития поражений печени, обусловленных противотуберкулезными средствами, показана возможность использования для гепатопротекции соединений на основе окисленного глутатиона
Due to the high frequency of liver lesions caused by antituberculosis drugs, the possibility of using compounds based on oxidized glutathione for hepatoprotection is shown
The purpose of the study was to conduct a comparative assessment of the hepatoprotective properties of molixan and glutoxim in liver lesions with anti-tuberculosis drugs
Summary
Согласно данным литературы применение изониазида в терапевтических дозах приводит к развитию у 20 % пациентов острого гепатоцеллюлярного некроза [8]. Что частота и тяжесть токсических поражений печени возрастает при комбинации изониазида с рифампицином вследствие индукции рифампицином цитохрома Р450 [8]. По данным зарубежных клинических исследований, из 3900 больных туберкулезом пациентов, получавших в качестве лечения комбинацию изониазида с рифампицином, у 150 (3,8 %) развивались лекарственно индуцированные поражения печени [10]. В настоящее время отсутствуют точные данные по возникновению фатальных поражений печени. Для профилактики токсических гепатопатий используют препараты, которые показали свою активность как в экспериментах, так и в клинических исследованиях. В настоящее время все больший интерес вызывают пептидные препараты на основе окисленного глутатиона, такие как моликсан и глутоксим, которые продемонстрировали свою эффективность при различных патологиях, в том числе при лечении хронических вирусных гепатитов В и С, острых крайне тяжелых отравлениях этанолом [1, 3, 9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
